Industry committee  No, I'm not saying what you're saying.

Industry committee  First of all, I think the problem is that.... And this is not coming from us. This is coming from the head of pharmacy of CHU Sainte-Justine. This is coming from pediatricians. This is coming from pharmacists across the country. When they adapt a product and they compound it, it'

Industry committee  That's right. And what we're saying is that, similar to the incentives, if there is a need for this for the population, Health Canada should look around to see how they can make these things more accessible. Maybe it's to give incentives where, if you do develop it, you have some

Industry committee  That's correct. Again, the big issue on this topic is about innovation. You have people coming to you and telling you they have a problem. The mother of invention is knowing that there is a problem and an unmet need. How do we make sure that those unmet needs end up being produ

Industry committee  I guess there are really two different things. Special access products are products that aren't approved for sale in Canada. Compounding is a way to adapt something that is approved for somebody else. Who pays for the compounding? It depends on the province and it depends on the

Industry committee  We're looking not to decrease what we have. The truth is, it would make life easier if we did have fewer, but that wouldn't, I think, be in the public good. I think we're saying that we think that the amount, the severity and the depth of an audit on an outsider should be the sam

Industry committee  The majority of the surveillance of foreign companies is done by foreign health authorities, because Health Canada doesn't have the resources to go around to all the countries where the products are made and do the inspections themselves.

Industry committee  There are a number of agreements mutually recognizing other health authorities' inspections, but when it comes down to whether the foreign health parties are asking all of Health Canada's questions the way that Health Canada is asking those questions, I don't think that's the cas

Industry committee  That's correct. The example Mr. Masterson gave also applies in some cases to pharmaceuticals and the treatment of excipients or other products that are incorporated in the products. If we do it here, we have to go through a rigorous pedigree and an audit, and the other side will

Industry committee  The fee that was proposed for us to pay for just Health Canada approval was $167,000.

Industry committee  You never know if Health Canada is going to approve it or not, so there's a risk at development.

Industry committee  The fees, no—every jurisdiction wants its own fees.

Industry committee  Yes.

Industry committee  In the case of Health Canada, there's no value added outside.

Industry committee  No.